SCHEMBL3757242

SCHEMBL3757242

Ic1cccc(-c2ncc3cn[nH]c3n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.47
NOS1 P29475 1/20 0.41
F2 P00734 1/20 0.37
FGFR1 P11362 2/20 0.35
DYRK3 O43781 1/20 0.35
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35
CLK3 P49761 1/20 0.35
GSK3B P49841 1/20 0.35
CDK5 Q00535 1/20 0.35
DYRK1A Q13627 1/20 0.35
CDK5R1 Q15078 1/20 0.35
DYRK2 Q92630 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
NUDT1 P36639 1/20 0.35
CYP1A2 P05177 1/20 0.34
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
FGFR2 P21802 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755550 0.81 IDO1 (0.47) METAP2CYP1A2
SCHEMBL3762000 0.80 HPGDS (0.47) FGFR1DYRK3CLK1CLK2CLK3
SCHEMBL3755620 0.78 CLK4 (0.54) DYRK1ACLK4CYP1A2
SCHEMBL28110427 0.74 CYP1A2 (0.58) METAP2CYP1A2ABCG2PDE4A
SCHEMBL20352369 0.74 METAP2 (0.52) METAP2DYRK1ACLK4CHRNB4CHRNA3
SCHEMBL9983071 0.73 CDC7 (0.51) FGFR1DYRK1BFGFR2FGFR3ROCK2
SCHEMBL9982819 0.71 CLK1 (0.46) FGFR1CLK1GSK3BPIM1MAPK13
SCHEMBL6055038 0.70 DYRK1A (0.42) METAP2NOS1FGFR1CLK2DYRK1A
SCHEMBL22715729 0.70 METAP2 (0.42) METAP2CLK2CDK5CLK4DYRK1B
SCHEMBL12966135 0.70 BTK (0.44) METAP2NOS1FGFR1DYRK3CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS NATCO PHARMA LIMITED (IN) 2010-11-25 US claimed
US-8349847-B2 Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents KONAKANCHI DURGA PRASAD (IN) 2013-01-08 US disclosed
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS NATCO PHARMA LIMITED (IN) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298351-A1 NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS DPYD, TYMP, TYMS METAP2 2633/4885NOS1 3165/4885F2 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.